Stay Informed

Sign up for news & alerts

Already signed up?
Login here

take action
For every $1 states spend dollar sign on substance misuse and addiction, 94 cents go to shovel up the consequences instead of for treatment and prevention. TELL YOUR LEGISLATORS

What Can I Do?



Continuing Education
Free online courses for addiction counselors LEARN ONLINE

Get Help
Need alcohol or drug help for yourself or someone else? GET HELP

 
FDA: Painkiller Ads Misleading
January 14, 2005

Share Share Email
Email
Print
Print
SubscribeSubscribe
News Summary

Pfizer Inc. ads for the painkillers Celebrex and Bextra mislead consumers and fail to properly disclose the drugs' side-effects, the U.S. Food and Drug Administration (FDA) told the pharmaceutical company.

Reuters reported Jan. 12 that the FDA cited five separate print and TV ads for making "unsubstantiated effectiveness claims."

However, the FDA said the letter sent to Pfizer on Jan. 10 was not a warning, but rather a statement of a potential problem. A Pfizer spokesperson said the company is in discussions with the agency on the matter and has agreed not to run more ads for Celebrex. She also said there is little consumer advertising of Bextra.

COMMENTS ON THIS ARTICLE:
(Comments now appear first to last)

Your Turn! Post a public comment (guidelines):

Name:

Comment:
(limit 250
words)
Enter this word
(help):		 Change

GUIDELINES: 
To keep this feature useful for everyone, please:

  1. Keep it clean, courteous, brief, and on-topic. Comments are for discussion of the above article, not general rants or manifestos. Serial comments intended to circumvent the 250-word limit may be deleted.

  2. Do not post promotional web links, personal information or requests for assistance (get help).

  3. Proof your comments carefully, use good spelling and punctuation, and don't use ALL CAPS. Comments are published immediately and cannot be edited.

Deceptive, slanderous and commercial posts are prohibited. We reserve the right to remove comments. (Report a comment).

Have questions or feedback? Contact us.